Navigation Links
Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death

physicians and patients immediately so that treatment decisions may be based on all the available evidence."

Richard Nesto, MD, Chairman of the Department of Cardiovascular Medicine at the Lahey Clinic Medical Center, said these new findings provide important information for physicians caring for diabetic patients. "Despite its limitations, the recent meta-analysis in the New England Journal of Medicine raised important questions about the cardiac safety of rosiglitazone. These questions can only be answered with better evidence from clinical trials. This interim analysis of RECORD, a randomized prospective clinical trial, helps to establish the overall cardiac safety profile of the drug," said Dr. Nesto, who is an author of the American Heart Association and American Diabetes Association consensus statement on the use of thiazolidinediones in diabetic patients with heart disease. "Additional clinical trials are underway to specifically address this issue, but the data from RECORD should be reassuring for physicians who need effective drugs to lower blood sugar levels -- the main cornerstone of treatment for diabetic patients."

The RECORD study's robust design and breadth make it uniquely suited to answer questions about cardiovascular risk with Avandia.

First, the study was designed to include a wide range of Type 2 diabetes patients, including those with and without existing cardiovascular disease, making it highly representative of real-world diabetes patients. Second, patients in RECORD were managed such that blood sugar remained within current guidelines, thereby eliminating a variable that may affect results, as inadequate blood sugar control is itself associated with cardiovascular events. Third, although an open-label design, each cardiovascular event was verified by an independent panel of physicians who did not know which medicines the patients were taking.

Under these rigorous standards, the interim analysis shows that the inci
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

Post Your Comments:
(Date:11/6/2009)...a., Nov. 6 In consultation with th...Consumer Healthcare, Division of McNEIL-PPC, Inc.,...ber of product lots of TYLENOL® Arthritis Pai...ed EZ-OPEN CAP. McNeil is initiating the recall af... associated with these lots that led to a small nu...
(Date:11/6/2009)...wswire/ -- Repossessions and liquidations of truck...er of 2009 declined as compared to similar figures... NasTrac Quarterly Index (NQI). The figures, cull...possessions and orderly liquidations, also indicat...nd printing equipment, offering mixed news on the ...
(Date:11/6/2009)...ewswire-FirstCall/ -- Derma Sciences, Inc. (OT...und care products, announced plans to release its ..., November 16, 2009. The Company will hold a confe... 11:00 am EST. Interested parties should call (866...onal), with passcode 81416481 to access the call. ...
Breaking Medicine Technology:McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Just Released New Poll 3A Healthcare Through Womens Eyes 60259 1Just Released New Poll 3A Healthcare Through Womens Eyes 60259 2Webmedx Reacts to News of Confidential Medical Records Being Sold on the Black Market 60255 1Webmedx Reacts to News of Confidential Medical Records Being Sold on the Black Market 60255 2VitaminSpice Appoints Dr Richard F Seelig as Director 5795 1VitaminSpice Appoints Dr Richard F Seelig as Director 5795 2
...25 Findings from an international,multicenter, ra... trial,evaluating ustekinumab (CNTO 1275) in the t...ll be presented for the first time at the 21st mee...akes place from Sept. 30 to,Oct. 5, 2007 in Buenos...O 1275 (anti-IL-12/23p40) Treatment of,Psoriasis: ...
...Drug,s Benefit, Alone and With Lipitor(R), in, O...and Triglycerides -, HAYWARD, Calif., Sept. 25 M...to the discovery and development of novel,therapeu... announced today,that it has begun a 180-patient P...tients with high cholesterol and triglycerides to ...
Other Medicine Technology:Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting 2Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
(Date:11/8/2009)...osts and Crushing Taxes Nail Nation,s Job Creators...-- In response to U.S. House passage of the health...preneurship Council (SBE Council) president & ... ,, "Make no mistake, those voting for H.R. 39...higher costs and crushing taxes and penalties. Eve...
(Date:11/8/2009)...ON, Nov. 8 Speaker Nanc...rence following the House passage of H.R. 3962, th...l passed by a vote of 220 to 215. Below are the S... colleagues just received a call from the Presiden...ng us on a great victory for the American people. ...
(Date:11/8/2009)...ON, Nov. 7 Tonight the ...lth Care for America Act, landmark health reform l...ess to quality, affordable, stable and secure heal...wn on some of the insurance industry,s worst pract...s and cut the deficit by $104 billion over ten yea...
(Date:11/8/2009)... New book called "Preventing and H.... Roberto Giraldo shows that AIDS is a result of m...y of so-called immune system stressor agents, whic...d most of all, emotional. , ...ov. 6 – 8, 2009, cell biologists, physicians...
(Date:11/8/2009)... 3D Global Solutions is pleased to anno...ng the proposal effort for ReSound who recently re...ring Aid contract. The award includes not only the...of Defense and other federal agencies. , ...009 -- 3D Global Solutions is pleased to announce ...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3
...N, Feb. 6 The U.S. Agency for,International Devel...y of,Zero Tolerance for Female Genital Cutting (FG... First Lady of the Federal Republic of Nigeria,spe...practice., Approximately 100 million to 140 milli...
...IS, Feb. 6 Worrell Inc., a full-service,product d...Shanghai, has,acquired the Montreal and San Diego ...ges Worrell Inc.,s industrial design prowess with ...ell. "We know how this business works. The Gad,Sha...
... currently expected to be February 21, 2008 ...ceived - Class action lawsuit settled...n Therapy,Services, Inc. (Nasdaq: RTSX ) (the "Co...d as of October 19, 2007 among,the Company, Radiat...
...f the Red Cross Annual Disaster Giving Program Pro...re weather and,tornadoes ripped through the South ...ommunities in Arkansas, Kentucky, Tennessee, Alaba...shelter, feeding victims and search and rescue wor...
..., Mass. (February 6, 2008)Perhaps the only positiv...a is that its relatively uncommon. Other than that...ends to strike people in the prime of their lives,...is poorly understood type of cancer. , One appro...
...N, Feb. 6 The Lupus Foundation of,America (LFA) i...atient,education series. Five new booklets and ele... information about lupus diagnosis and treatment.,... individuals and families. Developed in consultati...
Other Medicine News:Health News:From Kent Hill, USAID Assistant Administrator for Global Health on the Observance of International Day of Zero Tolerance 2Health News:Radiation Therapy Services, Inc. Shareholders Approve Merger Agreement 2Health News:Radiation Therapy Services, Inc. Shareholders Approve Merger Agreement 3Health News:American Red Cross Responds to Tornadoes in the Southeast 2Health News:Gene plays 'Jekyll and Hyde' in brain cancer 2Health News:Gene plays 'Jekyll and Hyde' in brain cancer 3Health News:Lupus Foundation of America Releases New Patient Education Series 2
...he widest offering of single-use instruments on th...long 43cm lengths for Bariatric Surgery. , Dual a...sulation covers the pivot points to reduce the cha...cord, which eliminates gapping at connection and t...
MultAcoice™™ Rongeur Handle With Ratchet and Monopolar Cautery
MultAcoice™ 5 mm Insulated Outer Shaft
...order products are offered as 1-piece or modular, ...ruments may be customized with handles of choice a...flush ports. Many standard patterns are available ...ffect delivery times. , Please Note: Individual ...
Medicine Products: